Keryx Biopharmaceuticals, Inc. (KERX) Raised to Neutral at Citigroup Inc.

Keryx Biopharmaceuticals, Inc. (KERX) Raised to Neutral at Citigroup Inc.


The brokerage presently has a $7.00 target price on the biopharmaceutical company's stock. Citigroup Inc.'s target price would indicate a potential upside of 11.82% from the stock's current price.



from Biotech News